Reduced toxicity, enhanced biocompatibilty, lower rates of infection, adhesion, calcification, and the promotion of endothelial lining.
Compared to what? In comparison with their past attempts, with the competition overall or with CardioCel?
Reduced toxicity, enhanced biocompatibilty, lower rates of...
-
- There are more pages in this discussion • 48 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.30 |
Change
-0.650(5.44%) |
Mkt cap ! $238.8M | |||
| Open | High | Low | Value | Volume |
| $11.71 | $11.83 | $11.24 | $346.8K | 29.94K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 90 | $11.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.50 | 50 | 1 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |